Guggenheim Adjusts Price Target on Merck & Co. to $170 From $146, Maintains Buy Rating

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, Intismeran Autogene, combined with Keytruda. The treatment extended survival without melanoma recurrence. MRNA stock surged 177%, MRK rose 12%. The vaccine's personalized nature and high cost may pose insurance coverage challenges. FDA approval is expected in 2027-2028. The treatment is not yet commercially priced, with estimates exceeding $150,000 per patient.

Merck's stock (MRK) is near its 52-week high, closing at $150.33 on Sept. 4, 4% below its peak. The company and Moderna (MRNA) reported positive phase III study results for their cancer therapy combo, meeting primary and key secondary endpoints. Keytruda, Merck's top-selling drug, drives over 55% of pharmaceutical sales and is key to the company's growth strategy. Merck is exploring new combinations and formulations to extend Keytruda's growth.

Merck and Moderna reported positive Phase 3 trial results for a personalized mRNA vaccine targeting melanoma, combined with Merck's Keytruda. The treatment improved recurrence-free survival, marking a potential first FDA-approved mRNA cancer therapy. The vaccine is customized using a patient's tumor DNA and RNA, teaching the immune system to target cancer cells. Costs and production time remain high, but experts anticipate advancements in manufacturing and AI-driven targeting.

Moderna and Merck's mRNA therapy intismeran, combined with KEYTRUDA, met Phase 3 trial endpoints for recurrence-free and distant-metastasis-free survival in high-risk melanoma patients. The trial enrolled 1,137 participants, but exact benefit sizes were not disclosed. The companies plan to present detailed data later. Intismeran is not yet available outside trials.

Moderna and Merck's mRNA cancer vaccine, Intismeran Autogene, reduced melanoma recurrence by 49% in a phase 3 trial when combined with Keytruda. The personalized vaccine uses mRNA to train immune cells to target melanoma. Researchers believe it could potentially work for other cancers, though effectiveness in metastatic settings remains uncertain.

Merck Animal Health was referred to the FTC and FDA for 'inaccurate and misleading' dosing claims on its Bravecto Quantum flea and tick treatment for dogs. The NARB found the claims misleading as they imply year-long protection for all tick species, while the FDA-approved interval is eight months for the lone star tick. Merck plans to appeal part of the decision.